EGFR and small cell lung carcinoma: Patients with EGFR mutations and wild-type TP53 benefit more from the combination treatments of EGFR-TKIs and bevacizumab,[28] which may be related to the fact that TP53 mutations are a poor prognostic factor in patients with TKI and participate in primary drug resistance of EGFR-TKIs by small-cell lung cancer (SCLC) transformation.[29–31] The detection of NGS during the treatments showed continuous change of EGFR mutation, which may be related to the dynamic regulation of drug resistance phenotype.